Martina Rauner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Martina Rauner has a total of 561 co-authors. Here are the top co-authors by number of shared publications:
- Lorenz Christian Hofbauer
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
42 shared publications Lorenz C. Hofbauer
Department of Medicine III Center for Healthy Aging, Medical Faculty, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
31 shared publicationsUlrike Baschant
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
24 shared publicationsSylvia Thiele
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
19 shared publications- Elena Tsourdi
Department of Medicine III & Center for Healthy Aging, Universitätsklinikum Dresden, Dresden, Germany
12 shared publications Elena Tsourdi
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
9 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2573-2583
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bo ne and Hem atology in E lderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS ( n = 111; 36% female) and age-matched controls ( n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [ p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [ p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [ p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
- 9 October 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2573-2583
Open AccessBone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bo ne and Hem atology in E lderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS ( n = 111; 36% female) and age-matched controls ( n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [ p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [ p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [ p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
- Open Access
- 10 June 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 32 (2) , 1-2
[Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
- 10 June 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 32 (2) , 1-2
Open Access[Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
- Open Access
- 11 May 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (8) , 1-13
Increased fracture risk associated with iron-deficiency anemia: a population-based propensity score matched cohort study
Summary Anemia seems to be associated with an increased risk of fracture. This cohort study of the UK primary care data shows in 84,932 anemic patients and 158,731 controls an increased fracture risk in anemic patients, also including patients < 50 years of age. Severe anemia was associated with 2 × vertebral fracture risk. Awareness of this clinically relevant association should increase. Purpose In this study, we evaluated the risk of fracture among adult patients with anemia, compared to propensity score matched controls, stratifying by fracture site, age, and severity of anemia. Methods We conducted a cohort study using the UK IQVIA Medical Research Database (IMRD), incorporating The Health Improvement Network (THIN), a Cegedim database. Adults with a diagnosis of anemia and an eligible hemoglobin value (< 13 g/dL (men) or < 12 g/dL (women)) were matched to controls using propensity score matching. Cox proportional hazard models estimated the hazard ratios (HRs) for the risk of any fracture (stratified by fracture site, sex, and age (defined < 50 years and > = 50 years)). Results 84,932 anemic patients were matched to 158,731 controls. Overall, anemia was associated with a significant 20% risk of any fracture (driven by a 32% (HR 1.32, 1.20–1.47) increase among males, no difference among females). When stratified by sex, males had a significant risk at all fracture sites (27% (HR 1.27, 1.03–1.58) risk for vertebral, 89% (HR 1.89, 1.52–2.34) risk for humerus fractures). In females, only hip (HR 1.14, 1.05–1.25) and vertebral fractures (HR 1.24, 1.07–1.43) were significantly associated with anemia. Patients ≥ 50 years had elevated risks for all sites. In patients < 50 years, only hip fracture was elevated (HR 1.86, 1.04–3.33). Conclusion Anemia was associated with a significant 20% increase of any fracture; however, this was driven by the elevated risk among males and those over the age of 50 years. Among females, only hip and vertebral fracture risk was elevated, while males had an elevated risk at all sites.
- 11 May 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (8) , 1-13
Open AccessIncreased fracture risk associated with iron-deficiency anemia: a population-based propensity score matched cohort study
Summary Anemia seems to be associated with an increased risk of fracture. This cohort study of the UK primary care data shows in 84,932 anemic patients and 158,731 controls an increased fracture risk in anemic patients, also including patients < 50 years of age. Severe anemia was associated with 2 × vertebral fracture risk. Awareness of this clinically relevant association should increase. Purpose In this study, we evaluated the risk of fracture among adult patients with anemia, compared to propensity score matched controls, stratifying by fracture site, age, and severity of anemia. Methods We conducted a cohort study using the UK IQVIA Medical Research Database (IMRD), incorporating The Health Improvement Network (THIN), a Cegedim database. Adults with a diagnosis of anemia and an eligible hemoglobin value (< 13 g/dL (men) or < 12 g/dL (women)) were matched to controls using propensity score matching. Cox proportional hazard models estimated the hazard ratios (HRs) for the risk of any fracture (stratified by fracture site, sex, and age (defined < 50 years and > = 50 years)). Results 84,932 anemic patients were matched to 158,731 controls. Overall, anemia was associated with a significant 20% risk of any fracture (driven by a 32% (HR 1.32, 1.20–1.47) increase among males, no difference among females). When stratified by sex, males had a significant risk at all fracture sites (27% (HR 1.27, 1.03–1.58) risk for vertebral, 89% (HR 1.89, 1.52–2.34) risk for humerus fractures). In females, only hip (HR 1.14, 1.05–1.25) and vertebral fractures (HR 1.24, 1.07–1.43) were significantly associated with anemia. Patients ≥ 50 years had elevated risks for all sites. In patients < 50 years, only hip fracture was elevated (HR 1.86, 1.04–3.33). Conclusion Anemia was associated with a significant 20% increase of any fracture; however, this was driven by the elevated risk among males and those over the age of 50 years. Among females, only hip and vertebral fracture risk was elevated, while males had an elevated risk at all sites.
- Open Access
- 6 March 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (5)
Thra knockout protects male mice from hyperthyroidism-driven cortical bone loss by mitigating bone resorption
Secondary osteoporosis is a major global health problem and can be caused by endocrine diseases, including hyperthyroidism. Of note, hyperthyroid mice exhibit both trabecular and cortical bone loss, accompanied by reduced bone strength, as a consequence of a high bone turnover in which bone resorption exceeds bone formation. Recently, we discovered that osteocytes in bones obtained from hyperthyroid mice develop osteoclast-like features. However, the role of thyroid hormone receptor α (TRα) in hyperthyroidism-driven bone resorption remains ill-defined. Here, we rendered male Thra0/0 mice (which lack all TRα isoforms) hyperthyroid, and comprehensively characterized their bone phenotype. Thra0/0 mice with L-thyroxine (T4) treatment displayed trabecular, but not cortical bone loss, and maintained bone strength, while T4-treated WT littermates showed overall reduced bone mass and strength. Serum levels of bone resorption marker tartrate-resistant acid phosphatase (TRAP) and numbers of TRAP-positive osteoclasts were elevated in hyperthyroid WT, but not Thra0/0 mice. We also detected increased numbers of TRAP-positive osteocytes in long bones of T4-treated WT mice. In line, the expression of osteoclast marker genes was upregulated with T4 in bone tissue from WT mice only. While thyroid hormones (THs) have been reported not to directly affect osteoclast activity, our in vitro studies using late osteoblasts/osteocytes derived from Thra0/0 and WT mice revealed that the TH-induced expression of osteoclast markers in these cells was Thra-dependent. Further, the Rankl/Opg ratio linking osteocytes to enhanced osteoclastogenesis was upregulated in hyperthyroid WT, but not Thra0/0 cells. Taken together, we demonstrate that Thra KO can preserve cortical bone mass and bone strength by obstructing an increase of bone-resorbing osteoclasts and osteocytes with osteoclast-like features in hyperthyroid male mice.
- 6 March 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (5)
Open AccessThra knockout protects male mice from hyperthyroidism-driven cortical bone loss by mitigating bone resorption
Secondary osteoporosis is a major global health problem and can be caused by endocrine diseases, including hyperthyroidism. Of note, hyperthyroid mice exhibit both trabecular and cortical bone loss, accompanied by reduced bone strength, as a consequence of a high bone turnover in which bone resorption exceeds bone formation. Recently, we discovered that osteocytes in bones obtained from hyperthyroid mice develop osteoclast-like features. However, the role of thyroid hormone receptor α (TRα) in hyperthyroidism-driven bone resorption remains ill-defined. Here, we rendered male Thra0/0 mice (which lack all TRα isoforms) hyperthyroid, and comprehensively characterized their bone phenotype. Thra0/0 mice with L-thyroxine (T4) treatment displayed trabecular, but not cortical bone loss, and maintained bone strength, while T4-treated WT littermates showed overall reduced bone mass and strength. Serum levels of bone resorption marker tartrate-resistant acid phosphatase (TRAP) and numbers of TRAP-positive osteoclasts were elevated in hyperthyroid WT, but not Thra0/0 mice. We also detected increased numbers of TRAP-positive osteocytes in long bones of T4-treated WT mice. In line, the expression of osteoclast marker genes was upregulated with T4 in bone tissue from WT mice only. While thyroid hormones (THs) have been reported not to directly affect osteoclast activity, our in vitro studies using late osteoblasts/osteocytes derived from Thra0/0 and WT mice revealed that the TH-induced expression of osteoclast markers in these cells was Thra-dependent. Further, the Rankl/Opg ratio linking osteocytes to enhanced osteoclastogenesis was upregulated in hyperthyroid WT, but not Thra0/0 cells. Taken together, we demonstrate that Thra KO can preserve cortical bone mass and bone strength by obstructing an increase of bone-resorbing osteoclasts and osteocytes with osteoclast-like features in hyperthyroid male mice.
- Open Access
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Deconstructing senescence phenotypes in cells of the bone and bone marrow
Cellular senescence in osteogenic mesenchymal cells contributes to age-related bone loss. The bone marrow hosts myeloid cells, the precursors of immune cells, as well as mesenchymal cells, which give rise to osteoblasts and osteocytes. The senotype and senolytic response of bone marrow cells, particularly hematopoietic cells, in age-related bone loss is unclear. In this issue, Doolittle et al. showed that of all immune cells, myeloid cells had the strongest senescence profile, yet the relative level of senescence remained lower than that of mesenchymal stromal cells. Mesenchymal cells displayed a profound senotype, rendering them susceptible to senolytic clearance protecting against bone loss. By contrast, selective clearance of p16 + myeloid cells was not long-lasting and, hence, did not fully protect against age-related bone loss. These findings underscore the challenges of developing senolytic strategies for tissues with mixed senotypes, such as bone.
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Open AccessDeconstructing senescence phenotypes in cells of the bone and bone marrow
Cellular senescence in osteogenic mesenchymal cells contributes to age-related bone loss. The bone marrow hosts myeloid cells, the precursors of immune cells, as well as mesenchymal cells, which give rise to osteoblasts and osteocytes. The senotype and senolytic response of bone marrow cells, particularly hematopoietic cells, in age-related bone loss is unclear. In this issue, Doolittle et al. showed that of all immune cells, myeloid cells had the strongest senescence profile, yet the relative level of senescence remained lower than that of mesenchymal stromal cells. Mesenchymal cells displayed a profound senotype, rendering them susceptible to senolytic clearance protecting against bone loss. By contrast, selective clearance of p16 + myeloid cells was not long-lasting and, hence, did not fully protect against age-related bone loss. These findings underscore the challenges of developing senolytic strategies for tissues with mixed senotypes, such as bone.
- Open Access
- 13 February 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (3) , 953-971
Iron overload induced by ferric derisomaltose and ferric carboxymaltose both increase FGF-23 levels and lead to osteomalacia and bone loss in normal mice
Ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) are key for treating iron deficiency anemia. However, FCM has been shown to raise serum fibroblast growth factor (FGF)-23 levels, causing hypophosphatemia and alterations in bone turnover in some patients. To date, it is unknown if FCM and FDI also affect bone mineralization. This study examined FDI and FCM effects on bone mineralization and FGF-23 in healthy mice, avoiding disease confounders. Male 12-week-old C57BL/6 J mice received single or weekly FDI, FCM, or placebo injections for 4 weeks.Repeated FDI and FCM injections affected body weight, blood counts, and caused significant liver iron accumulation and high serum iron. Both reduced most bone parameters by µCT; however, FCM showed falsely high bone density due to iron clusters in the bone marrow. Histology revealed greater bone volume loss with FCM than FDI (-36% FCM, p < 0.01; vs − 24% FDI, p < 0.05), predominantly from suppressed bone formation. Both iron formulations also led to a prominent increase in osteoid and FGF-23 (intact and C-terminal), raising the i:cFGF-23 ratio. A single dose led to similar, but milder effects than repeated dosing. In summary, repeated high doses of both, FDI and FCM, in healthy mice increased the i:cFGF-23 ratio and osteoid production, while reducing bone formation and volume.
- 13 February 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (3) , 953-971
Open AccessIron overload induced by ferric derisomaltose and ferric carboxymaltose both increase FGF-23 levels and lead to osteomalacia and bone loss in normal mice
Ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) are key for treating iron deficiency anemia. However, FCM has been shown to raise serum fibroblast growth factor (FGF)-23 levels, causing hypophosphatemia and alterations in bone turnover in some patients. To date, it is unknown if FCM and FDI also affect bone mineralization. This study examined FDI and FCM effects on bone mineralization and FGF-23 in healthy mice, avoiding disease confounders. Male 12-week-old C57BL/6 J mice received single or weekly FDI, FCM, or placebo injections for 4 weeks.Repeated FDI and FCM injections affected body weight, blood counts, and caused significant liver iron accumulation and high serum iron. Both reduced most bone parameters by µCT; however, FCM showed falsely high bone density due to iron clusters in the bone marrow. Histology revealed greater bone volume loss with FCM than FDI (-36% FCM, p < 0.01; vs − 24% FDI, p < 0.05), predominantly from suppressed bone formation. Both iron formulations also led to a prominent increase in osteoid and FGF-23 (intact and C-terminal), raising the i:cFGF-23 ratio. A single dose led to similar, but milder effects than repeated dosing. In summary, repeated high doses of both, FDI and FCM, in healthy mice increased the i:cFGF-23 ratio and osteoid production, while reducing bone formation and volume.
- 30 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (3)
1-Phosphatidylinositol 3-Phosphate 5-Kinase Inhibition by Apilimod Promotes an Adipocyte-Like Vascular Smooth Muscle Cell Phenotype and Prevents Arterial Calcification
BACKGROUND: Cardiovascular calcification is a significant predictor and contributor to cardiovascular diseases. Vascular smooth muscle cell (SMC)–derived extracellular vesicles (EVs) play a crucial role in microcalcification formation. EVs can originate from the endosomal system, and PIKFYVE (1-phosphatidylinositol 3-phosphate 5-kinase), a lipid kinase, plays a key role in endomembrane maturation. We hypothesize that PIKFYVE inhibition will modulate EV cargo and, thereby, arterial calcification. METHODS: Human coronary artery SMCs were cultured in osteogenic media to induce calcification. PIKFYVE inhibition was achieved using the pharmacological inhibitor apilimod and siRNA. We characterized the SMC phenotype and EVs through proteomics, transcriptomics, and kinomics. Ldlr -deficient mice fed a high-fat, high-cholesterol diet received apilimod for 5 weeks. RESULTS: Calcified human arteries and SMCs exhibited increased PIKFYVE protein expression compared with controls. In calcifying SMCs, phosphatidylinositol 3-phosphate levels were reduced but restored by apilimod. Apilimod prevented matrix mineralization and collagen deposition in calcifying SMCs, accompanied by reduced procollagen 1A1 secretion. Apilimod inhibited TNAP (tissue-nonspecific alkaline phosphatase) at mRNA, protein, and activity levels. EVs released from apilimod-treated calcifying SMCs exhibited lower mineral cargo, reduced aggregation potential, and diminished TNAP cargo. Phenotypic omics analyses revealed that apilimod induced a shift toward an adipocyte-like SMC phenotype, marked by upregulation of adipogenic TFs (transcription factors), fatty acid metabolism genes, and increased fatty acid uptake. Reactivation of YAP (Yes-associated protein)-TEAD (transcriptional enhancer factor) signaling partially reversed these phenotypic changes. In vivo, apilimod reduced vascular calcification and plaque TNAP activity but increased plaque lipid accumulation. CONCLUSIONS: Pharmacological inhibition of PIKFYVE disrupts YAP-TEAD signaling, thereby reducing arterial calcification by limiting the calcification potential of EVs and suppressing osteogenic SMC programming, but also induces an adipocyte-like SMC phenotype with lipid accumulation. These findings emphasize the need to consider SMC phenotypic plasticity and potential adverse effects when developing therapeutic strategies for arterial calcification.
- 30 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (3)
1-Phosphatidylinositol 3-Phosphate 5-Kinase Inhibition by Apilimod Promotes an Adipocyte-Like Vascular Smooth Muscle Cell Phenotype and Prevents Arterial Calcification
BACKGROUND: Cardiovascular calcification is a significant predictor and contributor to cardiovascular diseases. Vascular smooth muscle cell (SMC)–derived extracellular vesicles (EVs) play a crucial role in microcalcification formation. EVs can originate from the endosomal system, and PIKFYVE (1-phosphatidylinositol 3-phosphate 5-kinase), a lipid kinase, plays a key role in endomembrane maturation. We hypothesize that PIKFYVE inhibition will modulate EV cargo and, thereby, arterial calcification. METHODS: Human coronary artery SMCs were cultured in osteogenic media to induce calcification. PIKFYVE inhibition was achieved using the pharmacological inhibitor apilimod and siRNA. We characterized the SMC phenotype and EVs through proteomics, transcriptomics, and kinomics. Ldlr -deficient mice fed a high-fat, high-cholesterol diet received apilimod for 5 weeks. RESULTS: Calcified human arteries and SMCs exhibited increased PIKFYVE protein expression compared with controls. In calcifying SMCs, phosphatidylinositol 3-phosphate levels were reduced but restored by apilimod. Apilimod prevented matrix mineralization and collagen deposition in calcifying SMCs, accompanied by reduced procollagen 1A1 secretion. Apilimod inhibited TNAP (tissue-nonspecific alkaline phosphatase) at mRNA, protein, and activity levels. EVs released from apilimod-treated calcifying SMCs exhibited lower mineral cargo, reduced aggregation potential, and diminished TNAP cargo. Phenotypic omics analyses revealed that apilimod induced a shift toward an adipocyte-like SMC phenotype, marked by upregulation of adipogenic TFs (transcription factors), fatty acid metabolism genes, and increased fatty acid uptake. Reactivation of YAP (Yes-associated protein)-TEAD (transcriptional enhancer factor) signaling partially reversed these phenotypic changes. In vivo, apilimod reduced vascular calcification and plaque TNAP activity but increased plaque lipid accumulation. CONCLUSIONS: Pharmacological inhibition of PIKFYVE disrupts YAP-TEAD signaling, thereby reducing arterial calcification by limiting the calcification potential of EVs and suppressing osteogenic SMC programming, but also induces an adipocyte-like SMC phenotype with lipid accumulation. These findings emphasize the need to consider SMC phenotypic plasticity and potential adverse effects when developing therapeutic strategies for arterial calcification.
- 15 December 2025
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (1) , 49-67
Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review
Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis and constitutes an important health problem, associated with an increased risk of fractures, significant morbidity and mortality, and long-term decreased quality of life. Aging is linked to extensive multimorbidity, polypharmacy, physical and mental disability, and an increased risk of falls, rendering management of glucocorticoid-induced osteoporosis in the older population particularly challenging. On a pathophysiological level, aging is associated with declining osteoblast activity, increased osteoclast activity, and increased bone marrow adiposity; effects that are all accentuated by glucocorticoids. In this narrative review, we discuss the pathophysiology of glucocorticoid-induced osteoporosis, and focus on the mechanism of action, pharmacokinetics, and pharmacodynamics of the various pharmaceutical agents used in the treatment of glucocorticoid-induced osteoporosis, as well as their efficacy, tolerability and safety, especially in older individuals.
- 15 December 2025
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (1) , 49-67
Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review
Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis and constitutes an important health problem, associated with an increased risk of fractures, significant morbidity and mortality, and long-term decreased quality of life. Aging is linked to extensive multimorbidity, polypharmacy, physical and mental disability, and an increased risk of falls, rendering management of glucocorticoid-induced osteoporosis in the older population particularly challenging. On a pathophysiological level, aging is associated with declining osteoblast activity, increased osteoclast activity, and increased bone marrow adiposity; effects that are all accentuated by glucocorticoids. In this narrative review, we discuss the pathophysiology of glucocorticoid-induced osteoporosis, and focus on the mechanism of action, pharmacokinetics, and pharmacodynamics of the various pharmaceutical agents used in the treatment of glucocorticoid-induced osteoporosis, as well as their efficacy, tolerability and safety, especially in older individuals.
- Top Cited Papers
- 13 November 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 22 (1) , 42-61
Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Rheumatoid arthritis is an autoimmune disease that affects ~1% of the global population and leads to joint inflammation, local bone erosions and systemic bone loss. The disability and immobility caused by inflammatory bone loss, joint destruction and fractures in rheumatoid arthritis present a clinical challenge and impose a considerable socioeconomical burden. Osteoclasts have the unique ability to resorb bone and cause bone loss. A comprehensive understanding of the regulatory mechanisms of osteoclasts and their crosstalk with stromal cells, such as osteoblasts, or immune cells during inflammation is essential for the development of targeted therapies to prevent and treat bone loss. The objective of this Review is to present a comprehensive overview of the current knowledge of osteoclast regulation at different levels: from systemic pathways to changes in the bone microenvironment, including the involvement of local cells, to osteoclast-intrinsic regulation such as metabolic adaptations. We also discuss some of the current and emerging therapies that can counteract inflammatory bone loss.
- 13 November 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 22 (1) , 42-61
Top Cited PapersMechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Rheumatoid arthritis is an autoimmune disease that affects ~1% of the global population and leads to joint inflammation, local bone erosions and systemic bone loss. The disability and immobility caused by inflammatory bone loss, joint destruction and fractures in rheumatoid arthritis present a clinical challenge and impose a considerable socioeconomical burden. Osteoclasts have the unique ability to resorb bone and cause bone loss. A comprehensive understanding of the regulatory mechanisms of osteoclasts and their crosstalk with stromal cells, such as osteoblasts, or immune cells during inflammation is essential for the development of targeted therapies to prevent and treat bone loss. The objective of this Review is to present a comprehensive overview of the current knowledge of osteoclast regulation at different levels: from systemic pathways to changes in the bone microenvironment, including the involvement of local cells, to osteoclast-intrinsic regulation such as metabolic adaptations. We also discuss some of the current and emerging therapies that can counteract inflammatory bone loss.
- Open Access
- 13 July 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (10) , ziaf118
Comparison between dietary, parenteral, and genetic iron overload on bone health reveals secondary iron overload as a driver of cortical bone loss and fracture risk in mice
More than 18% of the global population suffers from osteoporosis and its associated fracture risk each year. Among the many factors implicated in osteoporosis development, high iron levels have been implicated in bone loss in mice and patients. Here, we performed a comparative analysis of the effect of iron overload induced via diet, injections, or genetic factors, on overall bone health and mechanical bone strength. We used female mice, given the higher risk of osteoporosis and associated fractures in women than in men. We show that dietary iron overload induced trabecular remodeling in the spine but not in the femur, with potentially pre-pathogenic structural changes. By contrast, iron injections caused severe bone deficits across all sites measured. Interestingly, the loss of cortical bone emerged as a common hallmark of secondary iron overload and was associated with decreased mechanical strength in mice. However, no bone anomalies were observed in mice with genetic iron overload, demonstrating that iron overload per se does not suffice to induce bone loss in genetic hemochromatosis. Collectively, our study shows that iron overload-induced by diet and injections, but not genetically, induces selective and specific bone deficits, which are associated with decreased bone mechanical strength in mice.
- 13 July 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (10) , ziaf118
Open AccessComparison between dietary, parenteral, and genetic iron overload on bone health reveals secondary iron overload as a driver of cortical bone loss and fracture risk in mice
More than 18% of the global population suffers from osteoporosis and its associated fracture risk each year. Among the many factors implicated in osteoporosis development, high iron levels have been implicated in bone loss in mice and patients. Here, we performed a comparative analysis of the effect of iron overload induced via diet, injections, or genetic factors, on overall bone health and mechanical bone strength. We used female mice, given the higher risk of osteoporosis and associated fractures in women than in men. We show that dietary iron overload induced trabecular remodeling in the spine but not in the femur, with potentially pre-pathogenic structural changes. By contrast, iron injections caused severe bone deficits across all sites measured. Interestingly, the loss of cortical bone emerged as a common hallmark of secondary iron overload and was associated with decreased mechanical strength in mice. However, no bone anomalies were observed in mice with genetic iron overload, demonstrating that iron overload per se does not suffice to induce bone loss in genetic hemochromatosis. Collectively, our study shows that iron overload-induced by diet and injections, but not genetically, induces selective and specific bone deficits, which are associated with decreased bone mechanical strength in mice.